{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:41:13Z","timestamp":1790890873170,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone\u00a0 (CHOP) therapy. Lenalidomide, which has been safely combined with CHOP to treat B-cell lymphoma, has shown efficacy as a single agent in AITL treatment. We performed a multicentric phase 2 trial combining 25 mg lenalidomide daily for 14 days per cycle with 8 cycles of CHOP21 in previously untreated AITL patients aged 60 to 80 years. The primary objective was the complete metabolic response (CMR) rate at the end of treatment. Seventy-eight of the 80 patients enrolled were included in the efficacy and safety analysis. CMR was achieved in 32 (41%; 95% confidence interval [CI], 30%-52.7%) patients, which was below the prespecified CMR rate of 55% defined as success in the study. The 2-year progression-free survival (PFS) was 42.1% (95% CI, 30.9%-52.8%), and the 2-year overall survival was 59.2% (95% CI, 47.3%-69.3%). The most common toxicities were hematologic and led to treatment discontinuation in 15% of patients. This large prospective and uniform series of AITL treatment data was used to perform an integrative analysis of clinical, pathologic, biologic, and molecular data. TET2, RHOA, DNMT3A, and IDH2 mutations were present in 78%, 54%, 32%, and 22% of patients, respectively. IDH2 mutations were associated with distinct pathologic and clinical features and DNMT3A was associated with shorter PFS. In conclusion, the combination of lenalidomide and CHOP did not improve the CMR in AITL patients. This trial clarified the clinical impact of recurrent mutations in AITL. This trial was registered at www.clincialtrials.gov as #NCT01553786.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003081","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T21:24:15Z","timestamp":1611437055000},"page":"539-548","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-5419","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"first","affiliation":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), H\u00f4pitaux Universitaires Henri Mondor, Unit\u00e9 H\u00e9mopathies Lympho\u00efdes, Cr\u00e9teil, France;"},{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Safar","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Clinique, Hospices Civils de Lyon, Pierre-B\u00e9nite, and Universit\u00e9 Lyon 1, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-9687","authenticated-orcid":false,"given":"Asma","family":"Beldi-Ferchiou","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"},{"name":"D\u00e9partement d\u2019H\u00e9matologie et d\u2019Immunologie Biologique, H\u00f4pitaux Universitaires Henri Mondor, AP-HP, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Nucl\u00e9aire, H\u00f4pital Cochin, AP-HP, Universit\u00e9 Paris Descartes, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Clinique, Hospices Civils de Lyon, Pierre-B\u00e9nite, and Universit\u00e9 Lyon 1, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie Clinique, Centre Hospitalo-Universitaire de Montpellier, Unit\u00e9 Mixte de Recherche\u2013Centre National de Recherche Scientifique 5535, Universit\u00e9 de Montpellier, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Fataccioli","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"},{"name":"D\u00e9partement de Pathologie, H\u00f4pitaux Universitaires Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Robe","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"},{"name":"D\u00e9partement de Pathologie, H\u00f4pitaux Universitaires Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Letourneau","sequence":"additional","affiliation":[{"name":"Institut de Pathologie, Centre Hospitalier Universitaire Vaudois et Universit\u00e9 de Lausanne, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-0117","authenticated-orcid":false,"given":"Edoardo","family":"Missiaglia","sequence":"additional","affiliation":[{"name":"Institut de Pathologie, Centre Hospitalier Universitaire Vaudois et Universit\u00e9 de Lausanne, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slim","family":"Fourati","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"},{"name":"Service de Virologie, D\u00e9partement Pr\u00e9vention, Diagnostic et Traitement des Infections, H\u00f4pitaux Universitaires Henri Mondor, AP-HP, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Moles-Moreau","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Angers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1430-2574","authenticated-orcid":false,"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Reims, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Institut Paoli-Calmette, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Voillat","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier, Chalon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Becker","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, Centre de Lutte Contre le Cancer Becquerel, Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bossard","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Nantes, Center Hospitalier Universitaire Nantes, D\u00e9partement de Pathologie, INSERM Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Parrens","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie, H\u00f4pital Haut-L\u00e9v\u00eaque, Pessac, INSERM U1053, Universit\u00e9 de Bordeaux, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cacheux","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Clermont Ferrand, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"R\u00e9gny","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier Universitaire, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie, Centre Henri Becquerel, Rouen, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-2343","authenticated-orcid":false,"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"},{"name":"D\u00e9partement d\u2019H\u00e9matologie et d\u2019Immunologie Biologique, H\u00f4pitaux Universitaires Henri Mondor, AP-HP, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meignan","sequence":"additional","affiliation":[{"name":"LYSA Image, H\u00f4pitaux Universitaires Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"de Leval","sequence":"additional","affiliation":[{"name":"Institut de Pathologie, Centre Hospitalier Universitaire Vaudois et Universit\u00e9 de Lausanne, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"},{"name":"D\u00e9partement de Pathologie, H\u00f4pitaux Universitaires Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0095-5379","authenticated-orcid":false,"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), H\u00f4pitaux Universitaires Henri Mondor, Unit\u00e9 H\u00e9mopathies Lympho\u00efdes, Cr\u00e9teil, France;"},{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, INSERM, Institut M\u00e9dical de Recherche Biom\u00e9dicale, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"issue":"18","key":"2021012216350669800_B1","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021012216350669800_B2","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"issue":"25","key":"2021012216350669800_B3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021012216350669800_B4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"de Leval","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2021012216350669800_B5","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2021012216350669800_B6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"issue":"7","key":"2021012216350669800_B7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2021012216350669800_B8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2021012216350669800_B9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2021012216350669800_B10","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2021012216350669800_B11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"2021012216350669800_B12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2021012216350669800_B13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"issue":"11","key":"2021012216350669800_B14","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2021012216350669800_B15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.4898","article-title":"TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma","volume":"242","author":"Schwartz","year":"2017","journal-title":"J Pathol"},{"issue":"1","key":"2021012216350669800_B16","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1038\/bcj.2016.122","article-title":"Identification of cell-type-specific mutations in nodal T-cell lymphomas","volume":"7","author":"Nguyen","year":"2017","journal-title":"Blood Cancer J"},{"issue":"16","key":"2021012216350669800_B17","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2021012216350669800_B18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021012216350669800_B19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-018-0145-9","article-title":"Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials","volume":"8","author":"Castellino","year":"2018","journal-title":"Blood Cancer J"},{"key":"2021012216350669800_B20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.5_2629","article-title":"ROBUST: First report of phase III randomized study of lenalidomide\/R-CHOP (R2-CHOP) vs placebo\/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"37","author":"Vitolo","year":"2019","journal-title":"Hematol Oncol"},{"issue":"9","key":"2021012216350669800_B21","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(18)30131-5","article-title":"Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study","volume":"5","author":"Tilly","year":"2018","journal-title":"Lancet Haematol"},{"issue":"13","key":"2021012216350669800_B22","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"4","key":"2021012216350669800_B23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/hon.2038","article-title":"Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up","volume":"31","author":"Fabbri","year":"2013","journal-title":"Hematol Oncol"},{"issue":"19","key":"2021012216350669800_B24","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2021012216350669800_B25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"27","key":"2021012216350669800_B26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021012216350669800_B27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2021012216350669800_B28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021012216350669800_B29","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"issue":"4","key":"2021012216350669800_B30","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2021012216350669800_B31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/(SICI)1096-9896(199603)178:3<303::AID-PATH475>3.0.CO;2-I","article-title":"VJ rearrangements of the TCR gamma locus in peripheral T-cell lymphomas: analysis by polymerase chain reaction and denaturing gradient gel electrophoresis","volume":"178","author":"Theodorou","year":"1996","journal-title":"J Pathol"},{"issue":"21","key":"2021012216350669800_B32","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2021012216350669800_B33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2021012216350669800_B34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41379-019-0254-4","article-title":"The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations","volume":"32","author":"Steinhilber","year":"2019","journal-title":"Mod Pathol"},{"issue":"52","key":"2021012216350669800_B35","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2021012216350669800_B36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"key":"2021012216350669800_B37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/hon.91_2630","article-title":"Phase I\/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma: phase II results","volume":"37","author":"Lunning","year":"2019","journal-title":"Hematol Oncol"},{"issue":"2","key":"2021012216350669800_B38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"issue":"12","key":"2021012216350669800_B39","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nm.4210","article-title":"DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling","volume":"22","author":"Guryanova","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"2021012216350669800_B40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"2021012216350669800_B41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2021012216350669800_B42","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/blood-2012-06-434639","article-title":"Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes","volume":"120","author":"Sekeres","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2021012216350669800_B43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"2021012216350669800_B44","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/2\/539\/1798446\/advancesadv2020003081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/2\/539\/1798446\/advancesadv2020003081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T21:24:22Z","timestamp":1611437062000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/2\/539\/474968\/Integrative-analysis-of-a-phase-2-trial-combining"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003081","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}